Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetics

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

To determine if the abnormal A-cell function of human diabetes can be corrected by insulin therapy, 10 patients with juvenile-type and 10 with adult-onset types of diabetes were aggressively treated with insulin for up to 10 days. Glucose, immunoreactive glucagon (IRG), and, where possible, insulin were measured in plasma specimens obtained at two-hour intervals for periods of up to 10 days. These patients were compared with nine nondiabetics who were studied similarly. During a two-day 'uncontrolled' period, marked hyperglycemia, glycosuria, and elevated IRG concentrations were present in both groups of diabetic patients. 'Improved control' was achieved in the juvenile-type diabetic group with an average insulin dose of 115±24 U. per day. Such therapy significantly reduced the mean plasma glucose (p<0.001) and IRG (p<0.05) concentrations when compared with the 'uncontrolled' period, but both remained above (p<0.05) the values seen in the nondiabetic subjects. 'Improved control' was achieved in the maturity-onset group of patients with an average insulin dose of 160±24 U. per day. This dose was associated with a mean plasma-insulin value of 106±26 μU. per milliliter, significantly greater (p<0.05) than that of the nondiabetic group. Mean plasma glucose (p<0.001) and IRG (p<0.02) concentrations were reduced significantly as compared with the 'uncontrolled' period; the mean IRG level was the same as that of the nondiabetics, but the mean plasma glucose levels remained significantly greater (p<0.001) than in the nondiabetics. The results indicate that aggressive administration of insulin by conventional means does significantly reduce the average IRG level in juvenile-type and adult-type diabetics. However, despite the large doses of insulin and unphysiologically high concentrations of circulating insulin in the juvenile-diabetic group, IRG remained significantly above that of the nondiabetics. In the adult-onset group, although it was reduced to normal, the IRG level can be viewed as above normal relative to the persistent hyperglycemia and hyperinsulinemia.

Original languageEnglish (US)
Pages (from-to)411-419
Number of pages9
JournalDiabetes
Volume27
Issue number4
StatePublished - 1978

Fingerprint

Glucagon
Insulin
Glucose
Therapeutics
Hyperglycemia
Glycosuria
Hyperinsulinism

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

@article{ece16b0d78fc426387ea261222d370e8,
title = "Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetics",
abstract = "To determine if the abnormal A-cell function of human diabetes can be corrected by insulin therapy, 10 patients with juvenile-type and 10 with adult-onset types of diabetes were aggressively treated with insulin for up to 10 days. Glucose, immunoreactive glucagon (IRG), and, where possible, insulin were measured in plasma specimens obtained at two-hour intervals for periods of up to 10 days. These patients were compared with nine nondiabetics who were studied similarly. During a two-day 'uncontrolled' period, marked hyperglycemia, glycosuria, and elevated IRG concentrations were present in both groups of diabetic patients. 'Improved control' was achieved in the juvenile-type diabetic group with an average insulin dose of 115±24 U. per day. Such therapy significantly reduced the mean plasma glucose (p<0.001) and IRG (p<0.05) concentrations when compared with the 'uncontrolled' period, but both remained above (p<0.05) the values seen in the nondiabetic subjects. 'Improved control' was achieved in the maturity-onset group of patients with an average insulin dose of 160±24 U. per day. This dose was associated with a mean plasma-insulin value of 106±26 μU. per milliliter, significantly greater (p<0.05) than that of the nondiabetic group. Mean plasma glucose (p<0.001) and IRG (p<0.02) concentrations were reduced significantly as compared with the 'uncontrolled' period; the mean IRG level was the same as that of the nondiabetics, but the mean plasma glucose levels remained significantly greater (p<0.001) than in the nondiabetics. The results indicate that aggressive administration of insulin by conventional means does significantly reduce the average IRG level in juvenile-type and adult-type diabetics. However, despite the large doses of insulin and unphysiologically high concentrations of circulating insulin in the juvenile-diabetic group, IRG remained significantly above that of the nondiabetics. In the adult-onset group, although it was reduced to normal, the IRG level can be viewed as above normal relative to the persistent hyperglycemia and hyperinsulinemia.",
author = "Philip Raskin and Unger, {Roger H}",
year = "1978",
language = "English (US)",
volume = "27",
pages = "411--419",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetics

AU - Raskin, Philip

AU - Unger, Roger H

PY - 1978

Y1 - 1978

N2 - To determine if the abnormal A-cell function of human diabetes can be corrected by insulin therapy, 10 patients with juvenile-type and 10 with adult-onset types of diabetes were aggressively treated with insulin for up to 10 days. Glucose, immunoreactive glucagon (IRG), and, where possible, insulin were measured in plasma specimens obtained at two-hour intervals for periods of up to 10 days. These patients were compared with nine nondiabetics who were studied similarly. During a two-day 'uncontrolled' period, marked hyperglycemia, glycosuria, and elevated IRG concentrations were present in both groups of diabetic patients. 'Improved control' was achieved in the juvenile-type diabetic group with an average insulin dose of 115±24 U. per day. Such therapy significantly reduced the mean plasma glucose (p<0.001) and IRG (p<0.05) concentrations when compared with the 'uncontrolled' period, but both remained above (p<0.05) the values seen in the nondiabetic subjects. 'Improved control' was achieved in the maturity-onset group of patients with an average insulin dose of 160±24 U. per day. This dose was associated with a mean plasma-insulin value of 106±26 μU. per milliliter, significantly greater (p<0.05) than that of the nondiabetic group. Mean plasma glucose (p<0.001) and IRG (p<0.02) concentrations were reduced significantly as compared with the 'uncontrolled' period; the mean IRG level was the same as that of the nondiabetics, but the mean plasma glucose levels remained significantly greater (p<0.001) than in the nondiabetics. The results indicate that aggressive administration of insulin by conventional means does significantly reduce the average IRG level in juvenile-type and adult-type diabetics. However, despite the large doses of insulin and unphysiologically high concentrations of circulating insulin in the juvenile-diabetic group, IRG remained significantly above that of the nondiabetics. In the adult-onset group, although it was reduced to normal, the IRG level can be viewed as above normal relative to the persistent hyperglycemia and hyperinsulinemia.

AB - To determine if the abnormal A-cell function of human diabetes can be corrected by insulin therapy, 10 patients with juvenile-type and 10 with adult-onset types of diabetes were aggressively treated with insulin for up to 10 days. Glucose, immunoreactive glucagon (IRG), and, where possible, insulin were measured in plasma specimens obtained at two-hour intervals for periods of up to 10 days. These patients were compared with nine nondiabetics who were studied similarly. During a two-day 'uncontrolled' period, marked hyperglycemia, glycosuria, and elevated IRG concentrations were present in both groups of diabetic patients. 'Improved control' was achieved in the juvenile-type diabetic group with an average insulin dose of 115±24 U. per day. Such therapy significantly reduced the mean plasma glucose (p<0.001) and IRG (p<0.05) concentrations when compared with the 'uncontrolled' period, but both remained above (p<0.05) the values seen in the nondiabetic subjects. 'Improved control' was achieved in the maturity-onset group of patients with an average insulin dose of 160±24 U. per day. This dose was associated with a mean plasma-insulin value of 106±26 μU. per milliliter, significantly greater (p<0.05) than that of the nondiabetic group. Mean plasma glucose (p<0.001) and IRG (p<0.02) concentrations were reduced significantly as compared with the 'uncontrolled' period; the mean IRG level was the same as that of the nondiabetics, but the mean plasma glucose levels remained significantly greater (p<0.001) than in the nondiabetics. The results indicate that aggressive administration of insulin by conventional means does significantly reduce the average IRG level in juvenile-type and adult-type diabetics. However, despite the large doses of insulin and unphysiologically high concentrations of circulating insulin in the juvenile-diabetic group, IRG remained significantly above that of the nondiabetics. In the adult-onset group, although it was reduced to normal, the IRG level can be viewed as above normal relative to the persistent hyperglycemia and hyperinsulinemia.

UR - http://www.scopus.com/inward/record.url?scp=0018130888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018130888&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 411

EP - 419

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 4

ER -